<DOC>
	<DOCNO>NCT01613482</DOCNO>
	<brief_summary>Evaluate survival without metastasis patient treat Trastuzumab association chemotherapy breast cancer express HER2-NEU .</brief_summary>
	<brief_title>TraStuzumAb-Radiotherapy : Impact Cerebral Prevention</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients breast cancer , express HER2NEU ( score +++ ICH ++ amplification FISH CISH , SISH ) Visceral metastasis , multiple First line metastasis treatment Trastuzumab association chemotherapy Good general condition : OMS= &lt; 2 Karnofsky &gt; =70 % Age &gt; 18 year &lt; 70 year Life expectancy &gt; =3 mois No Trastuzumab since 6 month No cerebral metastasis ( MRI ) Efficacy contraception woman genital capacity Consent sign patient Exclusion Criteria Contraindication IRM Psychiatric decease Prior cerebral radiotherapy , Geographical constraint , compromise fallow patient Infectious serious pathology , likely stop treatment Positive serology ( HIV , hBC , hBS ) Inclusion clinical trial 4 week th inclusion Pregnant breastfeeding woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>